BioVentrix undertakes first human application of Revivent-TC System

15 May 2016 (Last Updated May 15th, 2016 18:30)

US-based medical technology company BioVentrix has announced the first application of its Revivent-TC System with an endovascular catheter-based approach in a human from within the left ventricle.

Bioventrix

US-based medical technology company BioVentrix has announced the first application of its Revivent-TC System with an endovascular catheter-based approach in a human from within the left ventricle.

The less invasive ventricular enhancement or the LIVE procedure, which is used to reshape and reduce the left ventricle (LV), uses its micro-anchor technology to exclude scar tissue from within the vasculature and without opening the chest.

BioVentrix has reported a successful implant of its Revivent-TC System through the LIVE procedure in a 64-year-old female patient suffering from heart failure symptoms as a result of a myocardial infarction.

"This new endovascular delivery system to exclude the scar from within the LV cavity reduces procedural risk, improves accuracy of anchor implant, and enables a more minimally invasive approach for patients suffering from this disease."

The surgery was conducted by Interventional Cardiologist Dr Giedrius Davidavicius and Vilnius University Hospital cardiothoracic surgeon Dr Gintaras Kalinauskas.

Dr Davidavicius said: "This new endovascular delivery system to exclude the scar from within the LV cavity reduces procedural risk, improves accuracy of anchor implant, and enables a more minimally invasive approach for patients suffering from this disease."

The need for a more invasive surgery to implant the Revivent-TC System through the LIVE procedure is replaced by a closed-chest, endovascular approach which involves placing small titanium anchors along the outer surface of the heart and along one of the interior walls.

The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by almost 30-40%.


Image: A model of the human heart. Photo: courtesy of BioVentrix.